Clinical Trials Logo

Recurrent Disease clinical trials

View clinical trials related to Recurrent Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06088719 Recruiting - Breast Cancer Clinical Trials

Safety of Omitting Axillary Surgery in Breast Cancer Patients With Isolated Chest Wall Recurrence

Start date: January 1, 1989
Phase:
Study type: Observational

The axillary management of breast cancer patients with operable isolated chest wall recurrence after mastectomy is unclear. We aim to determine if axillary restaging surgery can be safely omitted with no increased recurrences in this group of patients.

NCT ID: NCT06014619 Recruiting - Skin Cancer Clinical Trials

Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs

Start date: August 1, 2023
Phase:
Study type: Observational

Mohs micro-graphic surgery (Mohs) is a tissue-sparing, surgical treatment for different types of skin cancer (e.g. basal cell carcinoma, squamous cell carcinoma, lentigo maligna (melanoma). It is a procedure performed with frozen sections. Slow Mohs, a variant of micro-graphic surgery, is performed by formalin fixation and paraffin-embedded sections. Both in Mohs and Slow Mohs tumor margins are assessed to achieve complete removal. This study aims to investigate the clinical presentation and outcomes (i.e. complications and recurrence rates) in patients treated with Mohs or Slow Mohs in the dermatology department of the Maastricht University Medical Center+ in Maastricht, the Netherlands.

NCT ID: NCT05432518 Recruiting - Glioblastoma Clinical Trials

Pilot Trial for Treatment of Recurrent Glioblastoma

Start date: June 27, 2023
Phase: Early Phase 1
Study type: Interventional

This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.

NCT ID: NCT05260671 Recruiting - Metastatic Cancer Clinical Trials

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Start date: January 25, 2022
Phase: Phase 2
Study type: Interventional

This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

NCT ID: NCT02747732 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (ibrutinib), in combination with bendamustine and rituximab (BR) in subjects with previously treated aggressive B cell non Hodgkin lymphoma (aB-NHL) including any subtype of diffuse large B cell lymphoma (DLBCL) primary mediastinal B cell lymphoma (PMBCL), double and triple hit DLBCL, transformed indolent lymphoma, unclassifiable aggressive B cell lymphoma between DLBCL and Burkitt lymphoma. Patients with CNS involvement (primary or secondary) will be excluded. Ibrutinib (IMBRUVICA®; PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently FDA approved for the treatment of relapsed Mantle cell lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) and waldenstrom Macroglobulinemia (WM).It is under constant investigation for the treatment of other B-cell malignancies. The initial approval of ibrutinib was received on 13 November 2013 by the United States Food and Drug Administration for the treatment of adult patients with MCL who have received at least 1 prior therapy. Ibrutinib has not been approved for marketing for the treatment of aggressive B cell lymphoma although Phase I trial in this setting has already been published. In Israel ibrutinib is registered for the treatment of MCL and CLL.